165 related articles for article (PubMed ID: 21669937)
1. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.
Papeix C; Depaz R; Tourbah A; Stankoff B; Lubetzki C
Mult Scler; 2011 Dec; 17(12):1520-2. PubMed ID: 21669937
[TBL] [Abstract][Full Text] [Related]
2. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis.
Habek M; Barun B; Puretić Z; Brinar VV
Ther Apher Dial; 2010 Jun; 14(3):298-302. PubMed ID: 20609182
[TBL] [Abstract][Full Text] [Related]
3. Severe relapse of multiple sclerosis during plasma exchange treatment.
Matzke B; Metze C; Winkelmann A; Grossmann A; Hartung HP; Benecke R; Zettl UK
Mult Scler; 2011 Jun; 17(6):759-62. PubMed ID: 21427132
[TBL] [Abstract][Full Text] [Related]
4. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
Berger JR
Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
[TBL] [Abstract][Full Text] [Related]
5. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
[TBL] [Abstract][Full Text] [Related]
6. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
[TBL] [Abstract][Full Text] [Related]
7. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
Bayas A; Penzien J; Hellwig K
Acta Neurol Scand; 2011 Oct; 124(4):290-2. PubMed ID: 21943035
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
[TBL] [Abstract][Full Text] [Related]
9. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
Baumgartner A; Stich O; Rauer S
Int J Neurosci; 2012 Jan; 122(1):35-9. PubMed ID: 21913869
[TBL] [Abstract][Full Text] [Related]
10. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
Castrop F; Kowarik MC; Albrecht H; Krause M; Haslinger B; Zimmer C; Berthele A; Hemmer B
Neurology; 2012 Mar; 78(12):928-30. PubMed ID: 22402856
[No Abstract] [Full Text] [Related]
11. Lethal multiple sclerosis relapse after natalizumab withdrawal.
Rigau V; Mania A; Béfort P; Carlander B; Jonquet O; Lassmann H; Camu W; Thouvenot E
Neurology; 2012 Nov; 79(22):2214-6. PubMed ID: 23100404
[No Abstract] [Full Text] [Related]
12. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab.
Kaufman MD; Lee R; Norton HJ
Mult Scler; 2011 Apr; 17(4):490-4. PubMed ID: 21135017
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
14. Failure of natalizumab to prevent relapses in neuromyelitis optica.
Kleiter I; Hellwig K; Berthele A; Kümpfel T; Linker RA; Hartung HP; Paul F; Aktas O;
Arch Neurol; 2012 Feb; 69(2):239-45. PubMed ID: 22332191
[TBL] [Abstract][Full Text] [Related]
15. [Natalizumab as induction therapy in multiple sclerosis].
Corlobé A; Charif M; Mania A; Outteryck O; de Sèze J; Labauge P
Rev Neurol (Paris); 2014 Jan; 170(1):2-5. PubMed ID: 24125463
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment.
Hellwig K; Haghikia A; Gold R
Mult Scler; 2011 Aug; 17(8):958-63. PubMed ID: 21613333
[TBL] [Abstract][Full Text] [Related]
17. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.
Rossi S; Motta C; Studer V; Monteleone F; De Chiara V; Buttari F; Barbieri F; Bernardi G; Battistini L; Cutter G; Stüve O; Salvetti M; Centonze D
Mult Scler; 2013 Jan; 19(1):59-68. PubMed ID: 22577119
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
19. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Arnal-Garcia C; García-Montero MR; Málaga I; Millán-Pascual J; Oliva-Nacarino P; Ramió-Torrentà L; Oreja-Guevara C
Eur J Paediatr Neurol; 2013 Jan; 17(1):50-4. PubMed ID: 23021975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
